Sverre Erik Kjeldsen

Hjertemedisinsk avdeling

English version of this page

E-post s.e.kjeldsen@medisin.uio.no

Mobiltelefon +4799224616

Rom Søsterhjemmet, 1. etasje mot Bygg 3

Treffetider Etter avtale

Brukernavn

Besøksadresse Ullevål sykehus Kirkeveien 166 0407 Oslo

Postadresse Postboks 4956 Nydalen OUS HF Ullevål sykehus 0424 Oslo

Last ned visittkort

Faglige interesser

Akuttmedisin inklusive akutte forgiftninger
Forskning relatert til hypertensjon; patofysiologi, epidemiologi og behandling
Hypertensiv hjertesykdom (venstre ventrikkel hypertrofi)
Evidence based medicine (randomized clinical trials)
Veiledet/medforfattet ca. 50 doktorgrader ved Universitet i Oslo

CITATION STATUS – SEPTEMBER 8, 2020

Web of Science H-index = 79 and Total Publications = 978

Sum of Times Cited = 51,183 by 34,476 Articles

Average Citations per Item = 52.33

PUB MED STATUS – April 2020: 710 publications

Undervisning

Klinisk kardiologi modul 3 og 8, tidligere 5. semester, forelesninger om utredning og behandling av hypertensjon, hjertesvikt, hjerteklaffefeil, hjerteinfarkt, atrieflimmer
Mangeårig leder for eksamenskommisjonen indremedisin og kirurgi
650 inviterte akademiske forelesninger internasjonale kongresser og foreninger
European Society of Hypertension Summer School 20 år
Visiting Faculty International Society of Hypertension and American College of Cardiology

Bakgrunn

Cand. med Universitetet i Oslo 1979; Dr. med. UiO 1984; ECFMG 1986
Spesialist indremedisin og kardiologi; utdannet ved Ullevål sykehus, Oslo og University of Michigan Hospital, Ann Arbor, Michigan, USA
Overlege akuttmedisinsk avdeling, Ullevål sykehus, 1989-1993
Seksjonsoverlege Hjertemedisinsk avdeling Ullevål sykehus 1993-2020
Sjefslege Hjerte-Lunge senteret Ullevål sykehus 1999-2005
Fellow American Heart Association (FAHA), European Society Cardiology (FESC) & American College Cardiology (FACC)
Professor II hjertemedisin UiO 2003-2020; emeritus fra 1.10.2020

Priser

International Society Hypertension Fellowship Award 1988
Cardiovasc Grand Rounds, Harvard Medical School, Boston 1989
Ullevaal University Hospital Research Award 1992
Blood Pressure Young Author Award 1997
Norwegian Society Cardiol (Ole Storstein’s) Scientific Award 2002
Ullevaal University Hospital Research Award 2003
Honorary Member Swedish Society of Hypertension 2004
Honorary Member Hungarian Society of Hypertenson 2005
Invited Lecturer, BHS Annual Scientific Meeting, Cambridge, UK 2007
Honorary Member Bulgarian Society of Hypertension 2007
Lennart Hansson Memorial Award and Lecture, ESH/ISH Berlin 2008
Honorary Member Polish Society of Hypertension 2008
Honorary Member Danish Society of Hypertension 2011
Harry Boström Memorial Lecture, Stockholm 2012
Hjerteprisen, Norwegian Council for Cardiovascular Diseases 2013
Robert Tigerstedt Award, Finish Society of Hypertension, Helsinki 2013
Thomson Reuter – most Highly Cited Researchers 2002-2012
Lecturer of the year, Belgisch Hypertensie Comité 2016
Thomson Reuter – most Highly Cited Researchers 2014-2016
Orkidépris (Orchid Prize), Norwegian Medical Association 2018
Alberto Zanchetti (European Society Hypertension) Life Time Achievement Award 2018
Oslo University Hospital Research Award (co-shared) 2018, 2019
Honorary Member of 1^st Academic China National Health Com 2019

Verv

Coordinator, Associate Chair, Executive Committee or Steering Committe member in RCT mega-trials (HOT, NORDIL, INSIGHT, LIFE, VALUE, ASCOT, ACCOMPLISH, SCAST)
Chair/Co-Chair BEAUTY, DISTINCT, OSLO-RDN, ENCOReD, Oslo Ischemia Study, IDA
Norwegian Society of Hypertension 1987-
Council European Society of Hypertension 1999-2009
President European Society of Hypertension 2005-07
Chair, 20th. Scientific Meeting European Society of Hypertension, Oslo 2010
Member 2003, 2007, 2013 og 2018 ESC/ESH Hypertension Guidelines Committes
Sekretær Hjertekirurgiutvalget Ullevål sykehus 1997
Medlem Helsedirektoratets ekspertgruppe for retningslinjer i forebyggende kardiologi
Editor in Chief, Blood Pressure 2016-
Editorial Board, HYPERTENSION.AHA
Clinical Trialist Reviewer Lancet

Samarbeid

Assistent Prof. of Medicine, University of Michigan, Ann Arbor, 1987-1989
Visiting Prof. of Medicine, U of Michigan, Ann Arbor, 1989-2002
Adjunct Prof. of Cardiovasc Medicine, U of Michigan, Ann Arbor, 2002-
Nasjonalt forskningssamarbeid Haukeland, St. Olav og Tromsø
Internasjonalt forskningssamarbeid med spesielt Imperial College, London; Oxford, UK; Sahlgrenska, Gøteborg; Karolinska, Stockholm; Glostrup, København; Helsinki, Finland; Pompidou, Paris; Milan-Bicocca, Milano; Padova, Italia; Lausanne, Sveits; Gdansk, Polen; Barcelona, Spania; Leuven og Brussel, Belgia; Shanghai og Beijing, Kina; Baker, Melbourne; University of Birmingham, Alabama; Weill Medical College of Cornell, New York; Northwestern University, Chicago; foruten University of Michigan, Ann Arbor

Emneord: Hypertensjon, Venstre Ventrikkel Hypertrofi, Clinical Trials

Mancia, Giuseppe; Brunström, Mattias; Burnier, Michel; Grassi, Guido; Januszewicz, Andrzej & Kjeldsen, Sverre [Vis alle 10 forfattere av denne artikkelen] (2024). Rationale for the Inclusion of β-Blockers among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. Hypertension. ISSN 0194-911X. 81(5), s. 1021–1030. doi: 10.1161/HYPERTENSIONAHA.124.22821.
Fadl Elmula, Fadl Elmula M.; Mariampillai, Julian Eek; Heimark, Sondre; Kjeldsen, Sverre & Burnier, Michel (2024). Medical Measures in Hypertensives Considered Resistant. American Journal of Hypertension. ISSN 0895-7061. 37(5), s. 307–317. doi: 10.1093/ajh/hpad118.
Mancia, Giuseppe; Brunström, Mattias; Burnier, Michel; Grassi, Guido; Januszewicz, Andrzej & Muiesan, Maria Lorenza [Vis alle 9 forfattere av denne artikkelen] (2024). Rationale of treatment recommendations in the 2023 ESH hypertension guidelines. European journal of internal medicine. ISSN 0953-6205. doi: 10.1016/j.ejim.2023.12.015.
Sevre, Kaja; Rist, Aurora; Wachtell, Kristian; Devereux, Richard B.; Aurigemma, Gerard P. & Smiseth, Otto Armin [Vis alle 14 forfattere av denne artikkelen] (2024). What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence. American Journal of Hypertension. ISSN 0895-7061. 37(1), s. 1–14. doi: 10.1093/ajh/hpad073.
Persu, Alexandre; Stoenoiu, Maria S.; Maes, Frédéric; Kreutz, Reinhold; Mancia, Giuseppe & Kjeldsen, Sverre (2023). Late outcomes of renal denervation are more favourable than early ones: facts or fancies. Clinical Kidney Journal (CKJ). ISSN 2048-8505. 16(12), s. 2357–2364. doi: 10.1093/ckj/sfad231. Fulltekst i vitenarkiv
Burnier, Michel; Narkiewicz, Krzysztof & Kjeldsen, Sverre (2023). How to optimize the use of diuretics in patients with heart failure? Kardiologia polska. ISSN 0022-9032. 81(10), s. 944–949. doi: 10.33963/v.kp.97315. Fulltekst i vitenarkiv
Mancia, Giuseppe; Kreutz, Reinhold; Brunström, Mattias; Burnier, Michel; Grassi, Guido & Januszewicz, Andrzej [Vis alle 59 forfattere av denne artikkelen] (2023). 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension. ISSN 0263-6352. 41(12), s. 1874–2071. doi: 10.1097/HJH.0000000000003480.
Rist, Aurora; Wachtell, Kristian; Holter Sevre, Kaja; Devereux, Richard B.; Aurigemma, Gerard P. & Smiseth, Otto Armin [Vis alle 14 forfattere av denne artikkelen] (2023). The current best drug treatment for hypertensive heart failure with preserved ejection fraction. European journal of internal medicine. ISSN 0953-6205. doi: 10.1016/j.ejim.2023.10.008. Fulltekst i vitenarkiv
Feinberg, Joshua B; Nielsen, Emil E; Kjeldsen, Sverre; Devereux, Richard B; Gerdts, Eva & Wachtell, Kristian [Vis alle 7 forfattere av denne artikkelen] (2023). Sex Differences in Atrial Fibrillation and Associated Complications in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study. American Journal of Hypertension. ISSN 0895-7061. 36(10), s. 536–541. doi: 10.1093/ajh/hpad057.
Heimark, Sondre; Mehlum, Maria Hollund; Mancia, Giuseppe; Søraas, Camilla Lund; Liestøl, Knut & Wachtell, Kristian [Vis alle 12 forfattere av denne artikkelen] (2023). Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg. Hypertension. ISSN 0194-911X. 80(8), s. 1739–1748. doi: 10.1161/HYPERTENSIONAHA.123.21454.
Brunström, Mattias; Carlberg, Bo & Kjeldsen, Sverre (2023). Effect of antihypertensive treatment in isolated systolic hypertension (ISH)–systematic review and meta-analysis of randomised controlled trials. Blood Pressure. ISSN 0803-7051. 32(1). doi: 10.1080/08037051.2023.2226757. Fulltekst i vitenarkiv
Halvorsen, Lene Vernås; Bergland, Ola Undrum; Søraas, Camilla Lund; Larstorp, Anne Cecilie Kjeldsen; Hjørnholm, Ulla & Kjær, Vibeke Norheim [Vis alle 14 forfattere av denne artikkelen] (2022). Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7-Year Follow-Up of Patients Considered Adherent by Directly Observed Therapy. Journal of the American Heart Association (JAHA). ISSN 2047-9980. 11(18). doi: 10.1161/JAHA.121.025879. Fulltekst i vitenarkiv Vis sammendrag
Background Measurement of serum concentrations of drugs is a novelty found useful in detecting poor drug adherence in patients taking ≥2 antihypertensive agents. Regarding patients with treatment‐resistant hypertension, we previously based our assessment on directly observed therapy. The present study aimed to investigate whether serum drug measurements in patients with resistant hypertension offer additional information regarding drug adherence, beyond that of initial assessment with directly observed therapy. Methods and Results Nineteen patients assumed to have true treatment‐resistant hypertension and adherence to antihypertensive drugs based on directly observed therapy were investigated repeatedly through 7 years. Serum concentrations of antihypertensive drugs were measured by ultra‐high‐performance liquid chromatography–tandem mass spectrometry from blood samples taken at baseline, 6‐month, 3‐year, and 7‐year visits. Cytochrome P450 polymorphisms, self‐reported adherence and beliefs about medicine were performed as supplement investigations. Seven patients (37%) were redefined as nonadherent based on their serum concentrations during follow‐up. All patients reported high adherence to medications. Nonadherent patients expressed lower necessity and higher concerns regarding intake of antihypertensive medication (P=0.003). Cytochrome P450 polymorphisms affecting metabolism of antihypertensive drugs were found in 16 patients (84%), 21% were poor metabolizers, and none were ultra‐rapid metabolizers. Six of 7 patients redefined as nonadherent had cytochrome P450 polymorphisms, however, not explaining the low serum drug concentrations measured in these patients. Conclusions Our data suggest that repeated measurements of serum concentrations of antihypertensive drugs revealed nonadherence in one‐third of patients previously evaluated as adherent and treatment resistant by directly observed therapy, thereby improving the accuracy of adherence evaluation. Registration URL: https://www.clinicaltrials.gov; unique identifier: NCT01673516.
Messerli, Franz H.; Bavishi, Chirag; Brguljan, Jana; Burnier, Michel; Dobner, Stephan & Elijovich, Fernando [Vis alle 21 forfattere av denne artikkelen] (2022). Renal denervation in the antihypertensive arsenal - knowns and known unknowns. Journal of Hypertension. ISSN 0263-6352. 40(10), s. 1859–1875. doi: 10.1097/HJH.0000000000003171.
Mancia, Giuseppe; Kjeldsen, Sverre; Kreutz, Reinhold; Pathak, Atul; Grassi, Guido & Esler, Murray (2022). Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension. ISSN 0194-911X. 79(6), s. 1153–1166. doi: 10.1161/HYPERTENSIONAHA.122.19020.
Bang, Casper N.; Greve, Anders M.; Køber, Lars; Muthiah, Anujan; Kjeldsen, Sverre & Julius, Stevo [Vis alle 9 forfattere av denne artikkelen] (2022). Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of medicine. ISSN 2692-3106. doi: 10.37349/emed.2022.00080.
Chinali, Marcello; Aurigemma, Gerard P.; Gerdts, Eva; Wachtell, Kristian; Okin, Peter M. & Muthiah, Anujan [Vis alle 10 forfattere av denne artikkelen] (2022). Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of medicine. ISSN 2692-3106. 3, s. 160–172. doi: 10.37349/emed.2022.00082.
Zacks, Eran S.; Stokke, Ildri Maria; Wachtell, Kristian; Hille, Darcy A.; Høieggen, Aud & Kjeldsen, Sverre [Vis alle 10 forfattere av denne artikkelen] (2022). Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study. Exploration of medicine. ISSN 2692-3106. 3(2), s. 128–138. doi: 10.37349/emed.2022.00079.
Bang, Casper N.; Li, Zhibin; Stokke, Ildri Maria; Kjeldsen, Sverre; Julius, Stevo & Hille, Darcy A. [Vis alle 9 forfattere av denne artikkelen] (2022). Incident left bundle branch block predicts cardiovascular events and death in hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of medicine. ISSN 2692-3106. 2022(3), s. 149–159. doi: 10.37349/emed.2022.00081.
Esler, Murray; Kjeldsen, Sverre; Pathak, Atul; Grassi, Guido; Kreutz, Reinhold & Mancia, Giuseppe (2022). Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. Blood Pressure. ISSN 0803-7051. 31(1), s. 210–224. doi: 10.1080/08037051.2022.2110858. Fulltekst i vitenarkiv
Lilja-Cyron, Alexander; Bang, Casper N.; Gerdts, Eva; Larstorp, Anne Cecilie Kjeldsen; Kjeldsen, Sverre & Julius, Stevo [Vis alle 9 forfattere av denne artikkelen] (2022). Aortic root dilatation in hypertensive patients with left ventricular hypertrophy–application of a new multivariate predictive model. The Life Study. Reviews in Cardiovascular Medicine (RCM). ISSN 1530-6550. 23(3), s. 1–10. doi: 10.31083/j.rcm2303095. Fulltekst i vitenarkiv Vis sammendrag
Background: Available nomograms to predict aortic root (AoR) diameter for body surface area have limitations. The purpose of this study was to evaluate the use of a new multivariate predictive model to identify AoR dilatation in hypertensive patients with left ventricular hypertrophy. Methods: 943 of 961 patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiographic sub-study had the necessary baseline characteristics and echocardiographic 2D measurements of AoR size to be included. Results: Predicted AoR (Sinus of Valsalva) diameter was 1.519 + (age [years] × 0.010) + (height [cm] × 0.010) – (gender [1 = M, 2 = F] × 0.247), and a measured AoR diameter exceeding the 97.5-percentile of this estimate was considered dilated. Measured AoR diameter was larger in men than in women (3.75 vs. 3.48 cm, p < 0.001) and AoR diameter predicted by the model was larger than predicted by nomogram (3.52 vs. 3.28 cm, p < 0.001). Using the multivariate model to identify patients with AoR dilatation, the prevalence was 13.7% in men and 12.3% in women (p = 0.537). There was consensus of AoR phenotype (normal/dilated) between model and nomogram in 92.8% of the patients. In multivariate logistic regression, AoR dilatation by model definition was predicted by presence of aortic regurgitation (OR 2.67, p < 0.001) and SD increase in age (OR 0.75, p = 0.023), pulse pressure (OR 0.64, p < 0.001), left ventricular mass index (OR 1.36, p = 0.08) and stroke volume (OR 1.45, p = 0.002), but not by body weight. Conclusions: Using the proposed model the prevalence of AoR dilatation was equal in men and women and the model seems to address the effects of gender, age and body size on AoR size.
Brunström, Mattias; Kjeldsen, Sverre; Kreutz, Reinhold; Gjesdal, Knut Tjøl; Narkiewicz, Krzysztof & Burnier, Michel [Vis alle 8 forfattere av denne artikkelen] (2021). Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective. Hypertension. ISSN 0194-911X. 78(2), s. 555–558. doi: 10.1161/HYPERTENSIONAHA.121.17356.
Copland, Emma; Canoy, Dexter; Nazarzadeh, Milad; Bidel, Zeinab; Ramakrishnan, Rema & Woodward, Mark [Vis alle 99 forfattere av denne artikkelen] (2021). Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. The Lancet Oncology. ISSN 1470-2045. 22(4), s. 558–570. doi: 10.1016/S1470-2045(21)00033-4.
Bergland, Ola Undrum; Halvorsen, Lene Vernås; Søraas, Camilla Lund; Hjørnholm, Ulla; Kjær, Vibeke Norheim & Rognstad, Stine [Vis alle 22 forfattere av denne artikkelen] (2021). Detection of Nonadherence to Antihypertensive Treatment by Measurements of Serum Drug Concentrations. Hypertension. ISSN 0194-911X. 78(3), s. 617–628. doi: 10.1161/HYPERTENSIONAHA.121.17514. Fulltekst i vitenarkiv Vis sammendrag
Nonadherence to drugs is a challenge in hypertension treatment. We aimed to assess the prevalence of nonadherence by serum drug concentrations compared with 2 indirect methods and relate to the prescribed drug regimens in a nationwide multicenter study. Five hundred fifty patients with hypertension using ≥2 antihypertensive agents participated. We measured concentrations of 23 antihypertensive drugs using ultra high performance liquid chromatography tandem mass-spectrometry and compared with patients’ self-reports and investigators’ assessment based on structured interview. We identified 40 nonadherent patients (7.3%) using serum drug concentrations. They had higher office diastolic blood pressure (90 versus 83 mm Hg, P<0.01) and daytime diastolic blood pressure (85 versus 80 mm Hg, P<0.01) though systolic blood pressures did not differ significantly. They had more prescribed daily antihypertensive pills (2.5 versus 2.1 pills, P<0.01) and total daily pills (5.5 versus 4.4 pills, P=0.03). Prescription of fixed-dose combination pills were lower among the nonadherent patients identified by serum concentrations (45.0 versus 67.1%, P<0.01). Fifty-three patients self-reported nonadherence, while the investigators suspected 69 nonadherent patients. These groups showed no or few differences in drug regimens, respectively. In summary, we detected 7.3% prevalence of nonadherence by serum drug measurements in patients using ≥2 antihypertensive agents in a nationwide study; they had higher office and ambulatory diastolic blood pressures, higher number of prescribed daily pills, more daily antihypertensive pills, and less frequent prescriptions of fixed-dose combination pills. Indirect methods showed poor overlap with serum drugs concentrations and no or minimal medication differences. Thus, serum measurements of drugs were useful in detection and characterization of nonadherence to antihypertensive treatment.
Kasiakogias, Alexandros; Rosei, Enrico Agabiti; Camafort, Miguel; Ehret, Georg; Faconti, Luca & Ferreira, João Pedro [Vis alle 19 forfattere av denne artikkelen] (2021). Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension. ISSN 0263-6352. 39(8), s. 1522–1545. doi: 10.1097/HJH.0000000000002910. Fulltekst i vitenarkiv
Falk, Ragnhild Sørum; Mariampillai, Julian Eek; Prestgaard, Erik Edvard; Heir, Trond; Bodegard, Johan & Robsahm, Trude Eid [Vis alle 18 forfattere av denne artikkelen] (2021). The Oslo Ischaemia Study: cohort profile. BMJ Open. ISSN 2044-6055. 11(10). doi: 10.1136/bmjopen-2021-049111. Fulltekst i vitenarkiv Vis sammendrag
Abstract Purpose The Oslo Ischaemia Study was designed to investigate the prevalence and predictors of silent coronary disease in Norwegian middle-aged men, specifically validating exercise electrocardiography (ECG) findings compared with angiography. The study has been important in investigating long-term predictors of cardiovascular morbidity and mortality, as well as investigating a broad spectrum of epidemiological and public health perspectives. Participants In 1972–1975, 2014 healthy men, 40–59 years old, were enrolled in the study. Comprehensive clinical examination included an ECG-monitored exercise test at baseline and follow-ups. The cohort has been re-examined four times during 20 years. Linkage to health records and national health registries has ensured complete endpoint registration of morbidity until the end of 2006, and cancer and mortality until the end of 2017. Findings to date The early study results provided new evidence, as many participants with a positive exercise ECG, but no chest pain (‘silent ischaemia’), did not have significant coronary artery stenosis after all. Still, they were over-represented with coronary disease after years of follow-up. Furthermore, participants with the highest physical fitness had lower risk of cardiovascular disease, and the magnitude of blood pressure responses to moderate exercise was shown to influence the risk of cardiovascular disease and mortality. With time, follow-up data allowed the scope of research to expand into other fields of medicine, with the aim of investigating predictors and the importance of lifestyle and risk factors. Future plans Recently, the Oslo Ischaemia Study has been found worthy, as the first scientific study, to be preserved by The National Archives of Norway. All the study material will be digitised, free to use and accessible for all. In 2030, the Oslo Ischaemia Study will be linked to the Norwegian Cause of Death Registry to obtain complete follow-up to death. Thus, a broad spectrum of additional opportunities opens.
Mariampillai, Julian Eek; Prestgaard, Erik Edvard; Kjeldsen, Sverre; Liestøl, Knut; Grundvold, Irene & Bodegard, Johan [Vis alle 9 forfattere av denne artikkelen] (2021). Novel insights into stroke risk beyond resting and maximal bicycle exercise systolic blood pressure. Journal of Hypertension. ISSN 0263-6352. 39(10), s. 2022–2029. doi: 10.1097/HJH.0000000000002894.
Parati, Gianfranco; Kjeldsen, Sverre; Coca, Antonio; Cushman, William C. & Wang, Jiguang (2021). Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension. ISSN 0194-911X. 77(2), s. 692–705. doi: 10.1161/HYPERTENSIONAHA.120.15781. Fulltekst i vitenarkiv
Olsen, Eirik; Holzhauer, Björn; Julius, Stevo; Kjeldsen, Sverre; Larstorp, Anne Cecilie Kjeldsen & Mancia, Giuseppe [Vis alle 12 forfattere av denne artikkelen] (2021). Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. Blood Pressure. ISSN 0803-7051. 30. doi: 10.1080/08037051.2020.1856642. Fulltekst i vitenarkiv
Olsen, Eirik; Holzhauer, Björn; Julius, Stevo; Kjeldsen, Sverre; Larstorp, Anne Cecilie Kjeldsen & Mancia, Giuseppe [Vis alle 12 forfattere av denne artikkelen] (2021). Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. Blood Pressure. ISSN 0803-7051. doi: 10.1080/08037051.2020.1855968. Fulltekst i vitenarkiv
Kjeldsen, Sverre & Os, Ingrid (2020). Assessing hypertension therapies: randomization or confounding by indication? Nature Reviews Cardiology. ISSN 1759-5002. 17(2), s. 73–74. doi: 10.1038/s41569-019-0313-z.
Mahfoud, Felix; Azizi, Michel; Ewen, Sebastian; Pathak, Atul; Ukena, Christian & Blankestijn, Peter J [Vis alle 31 forfattere av denne artikkelen] (2020). Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. European Heart Journal. ISSN 0195-668X. 41(16), s. 1588–1599. doi: 10.1093/eurheartj/ehaa121.
Burnier, Michel; Kreutz, Reinhold; Narkiewicz, Krzysztof; Kjeldsen, Sverre; Oparil, Suzanne & Mancia, Giuseppe (2020). Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: Is dosing in the evening better than in the morning? Journal of Hypertension. ISSN 0263-6352. 38(8), s. 1396–1406. doi: 10.1097/HJH.0000000000002532.
Mehlum, Maria Hollund; Liestøl, Knut; Kjeldsen, Sverre; Wyller, Torgeir Bruun; Julius, Stevo & Rothwell, Peter M. [Vis alle 10 forfattere av denne artikkelen] (2020). Blood pressure-lowering profiles and clinical effects of angiotensin receptor blockers versus calcium channel blockers. Hypertension. ISSN 0194-911X. 75(6), s. 1584–1592. doi: 10.1161/HYPERTENSIONAHA.119.14443.
Prestgaard, Erik Edvard; Mariampillai, Julian Eek; Engeseth, Kristian; Erikssen, Jan Emil; Bodegard, Johan & Liestøl, Knut [Vis alle 9 forfattere av denne artikkelen] (2020). Change in body weight and long-term risk of stroke and death in healthy men. Stroke. ISSN 0039-2499. 51(5), s. 1435–1441. doi: 10.1161/STROKEAHA.119.027233.
Mirza, Yusuf Ahmed; Prestgaard, Erik Edvard; Selmer, Randi Marie; Liestøl, Knut; Grundvold, Irene & Erikssen, Jan Emil [Vis alle 8 forfattere av denne artikkelen] (2020). Tiårsprediksjon av hjerte-og karsykdom hos friske norske menn basert på NORRISK-2. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 140(12), s. 1–10. doi: 10.4045/tidsskr.20.0089. Fulltekst i vitenarkiv
Kjeldsen, Sverre; Halvorsen, Sigrun; Wyller, Torgeir Bruun; Bath, Philip M. & Sandercock, Peter (2020). Eivind Berge, MD, PhD, 1964-2020: Cardiologist Who Was Fighting Stroke. Stroke. ISSN 0039-2499. 51(5), s. 1353–1355. doi: 10.1161/STROKEAHA.120.029351.
Willeit, Peter; Tschiderer, Lena; Allara, Elias; Reuber, Kathrin; Seekircher, Lisa & Gao, Lu [Vis alle 76 forfattere av denne artikkelen] (2020). Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk : Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. Circulation. ISSN 0009-7322. 142(7), s. 621–642. doi: 10.1161/CIRCULATIONAHA.120.046361. Vis sammendrag
Background: To quantify the association between effects of interventions on carotid intima-media thickness (cIMT) progression and their effects on cardiovascular disease (CVD) risk. Methods: We systematically collated data from randomized, controlled trials. cIMT was assessed as the mean value at the common-carotid-artery; if unavailable, the maximum value at the common-carotid-artery or other cIMT measures were used. The primary outcome was a combined CVD end point defined as myocardial infarction, stroke, revascularization procedures, or fatal CVD. We estimated intervention effects on cIMT progression and incident CVD for each trial, before relating the 2 using a Bayesian meta-regression approach. Results: We analyzed data of 119 randomized, controlled trials involving 100 667 patients (mean age 62 years, 42% female). Over an average follow-up of 3.7 years, 12 038 patients developed the combined CVD end point. Across all interventions, each 10 μm/y reduction of cIMT progression resulted in a relative risk for CVD of 0.91 (95% Credible Interval, 0.87–0.94), with an additional relative risk for CVD of 0.92 (0.87–0.97) being achieved independent of cIMT progression. Taken together, we estimated that interventions reducing cIMT progression by 10, 20, 30, or 40 μm/y would yield relative risks of 0.84 (0.75–0.93), 0.76 (0.67–0.85), 0.69 (0.59–0.79), or 0.63 (0.52–0.74), respectively. Results were similar when grouping trials by type of intervention, time of conduct, time to ultrasound follow-up, availability of individual-participant data, primary versus secondary prevention trials, type of cIMT measurement, and proportion of female patients. Conclusions: The extent of intervention effects on cIMT progression predicted the degree of CVD risk reduction. This provides a missing link supporting the usefulness of cIMT progression as a surrogate marker for CVD risk in clinical trials.
Holanger, Magnus; Kjeldsen, Sverre; Jamerson, Kenneth & Julius, Stevo (2020). Smoking and overweight associated with masked uncontrolled hypertension: a Hypertension Optimal Treatment (HOT) Sub-Study. Blood Pressure. ISSN 0803-7051. s. 1–9. doi: 10.1080/08037051.2020.1787815. Fulltekst i vitenarkiv
Okin, Peter M.; Hille, Darcy A.; Wachtell, Kristian; Kjeldsen, Sverre Erik; Julius, Stevo & Devereux, Richard B. (2020). On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Blood Pressure. ISSN 0803-7051. 29(5), s. 319–326. doi: 10.1080/08037051.2020.1782171. Fulltekst i vitenarkiv
Kjeldsen, Sverre; von Lueder, Thomas Gero; Smiseth, Otto A.; Wachtell, Kristian; Mistry, Nisha & Westheim, Arne [Vis alle 12 forfattere av denne artikkelen] (2019). Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension. ISSN 0194-911X. doi: 10.1161/HYPERTENSIONAHA.119.14057. Fulltekst i vitenarkiv
Mariampillai, Julian Eek; Liestøl, Knut; Kjeldsen, Sverre; Prestgaard, Erik Edvard; Engeseth, Kristian & Bodegard, Johan [Vis alle 11 forfattere av denne artikkelen] (2019). Exercise Systolic Blood Pressure at Moderate Workload Is Linearly Associated With Coronary Disease Risk in Healthy Men. Hypertension Research. ISSN 0916-9636. 75(1), s. 44–50. doi: 10.1161/HYPERTENSIONAHA.119.13528. Fulltekst i vitenarkiv
Egan, Brent M; Kjeldsen, Sverre; Grassi, Guido; Esler, Murray D. & Mancia, Giuseppe (2019). The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? Journal of Hypertension. ISSN 0263-6352. 37(6), s. 1148–1153. doi: 10.1097/HJH.0000000000002021. Fulltekst i vitenarkiv
Larstorp, Anne Cecilie Kjeldsen; Stokke, Ildri Maria; Kjeldsen, Sverre; Hecht Olsen, Michael; Okin, Peter M. & Devereux, Richard B [Vis alle 7 forfattere av denne artikkelen] (2019). Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. Blood Pressure. ISSN 0803-7051. 28(5), s. 317–326. doi: 10.1080/08037051.2019.1633905. Fulltekst i vitenarkiv
Kjeldsen, Sverre; Aksnes, Tonje Amb; Mo, Rune & Klemsdal, Tor Ole (2019). Impact of the new ACC/AHA and ESC/ESH hypertension guidelines for Norway. European Heart Journal. ISSN 0195-668X. 40(19), s. 1485–1487. doi: 10.1093/eurheartj/ehz266.
Kjeldsen, Sverre; Os, Ingrid & Westheim, Anne (2019). Could adverse events offset the benefit of intensive blood pressure lowering treatment in the Systolic Blood Pressure Intervention Trial? Journal of Hypertension. ISSN 0263-6352. 37(5), s. 902–904. doi: 10.1097/HJH.0000000000002018.
Smiseth, Otto A.; Kjeldsen, Sverre; Andersen, Øyvind Senstad; Mistry, Nisha; Westheim, Arne & Skulstad, Helge [Vis alle 7 forfattere av denne artikkelen] (2019). Hjertesvikt med normal ejeksjonsfraksjon. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 139(6), s. 522–527. doi: 10.4045/tidsskr.18.0523.
Okin, Peter M.; Kjeldsen, Sverre & Devereux, Richard B (2019). Effect of antihypertensive therapy on development of incident conduction system disease in hypertensive patients. Journal of Hypertension. ISSN 0263-6352. 37(3), s. 629–635. doi: 10.1097/HJH.0000000000001915.
Stokke, Ildri Maria; Li, Zhi Bin; Cicala, Silvana; Okin, Peter M.; Kjeldsen, Sverre & Devereux, Richard B [Vis alle 7 forfattere av denne artikkelen] (2019). Association of left bundle branch block with new onset abnormal wall motion in treated hypertensive patients with left ventricle hypertrophy: the LIFE Echo Sub-study. Blood Pressure. ISSN 0803-7051. 28(2), s. 84–92. doi: 10.1080/08037051.2019.1569463. Fulltekst i vitenarkiv
Mariampillai, Julian Eek; Prestgaard, Erik Edvard; Kjeldsen, Sverre; Liestøl, Knut; Engeseth, Kristian & Erikssen, Jan Emil [Vis alle 10 forfattere av denne artikkelen] (2019). SBP above 180 mmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-up. Journal of Hypertension. ISSN 0263-6352. 37(5), s. 949–955. doi: 10.1097/HJH.0000000000001959.
Prestgaard, Erik Edvard; Mariampillai, Julian Eek; Engeseth, Kristian; Erikssen, Jan Emil; Bodegard, Johan & Liestøl, Knut [Vis alle 10 forfattere av denne artikkelen] (2018). Change in Cardiorespiratory Fitness and Risk of Stroke and Death. Stroke. ISSN 0039-2499. 50, s. 155–161. doi: 10.1161/STROKEAHA.118.021798.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2018). Take a blood pressure pill or benefit from renal denervation? European Heart Journal. ISSN 0195-668X. 39(33), s. 3010–3012. doi: 10.1093/eurheartj/ehy440.
Williams, Bryan; Mancia, Giuseppe; Spiering, Wilko; Agabiti Rosei, Enrico; Azizi, Michel & Burnier, Michel [Vis alle 28 forfattere av denne artikkelen] (2018). 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Blood Pressure. ISSN 0803-7051. 27(6), s. 314–340. doi: 10.1080/08037051.2018.1527177.
Hjørnholm, Ulla; Aamodt, Josephine Jeanette Mikaela; Larstorp, Anne Cecilie Kjeldsen; Fadl Elmula, Fadl Elmula M.; Høieggen, Aud & Andersen, Marit Helen [Vis alle 7 forfattere av denne artikkelen] (2018). Directly Observed Therapy in Hypertension (DOT-HTN). I Burnier, Michel (Red.), Drug Adherence in Hypertension and Cardiovascular Protection . Springer Nature. ISSN 978-3-319-76592-1. s. 57–85. doi: 10.1007/978-3-319-76593-8_6.
Mehlum, Maria Hollund; Liestøl, Knut; Kjeldsen, Sverre; Julius, Stevo; Hua, Tsushung A. & Rothwell, Peter M. [Vis alle 10 forfattere av denne artikkelen] (2018). Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. European Heart Journal. ISSN 0195-668X. 39(24), s. 2243–2251. doi: 10.1093/eurheartj/ehx760.
Engeseth, Kristian; Prestgaard, Erik Edvard; Mariampillai, Julian Eek; Grundvold, Irene; Liestøl, Knut & Kjeldsen, Sverre [Vis alle 10 forfattere av denne artikkelen] (2018). Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged men. European Journal of Preventive Cardiology (EJPC). ISSN 2047-4873. 25(15), s. 1655–1663. doi: 10.1177/2047487318793459.
Heimark, Sondre; Mariampillai, Julian Eek; Narkiewicz, Krzysztof; Nilsson, Peter M. & Kjeldsen, Sverre (2018). Which Target Blood Pressure in Year 2018? Evidence from Recent Clinical Trials. High Blood Pressure & Cardiovascular Prevention. ISSN 1120-9879. 25(2), s. 151–158. doi: 10.1007/s40292-018-0258-z.
Kjeldsen, Sverre & Wachtell, Kristian (2017). Consensus document on hypertension and cardiac arrhythmias. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 3(4), s. 251–252. doi: 10.1093/ehjcvp/pvx022.
Okin, Peter M.; Kjeldsen, Sverre & Devereux, Richard B. (2017). The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study. Journal of Hypertension. ISSN 0263-6352. 36(4), s. 916–923. doi: 10.1097/HJH.0000000000001620.
Lüscher, Thomas F.; Kjeldsen, Sverre; Mancia, Giuseppe & Papademetriou, Vasilios (2017). From ‘essential’ hypertension to intensive blood pressure lowering: the pros and cons of lower target values. European Heart Journal. ISSN 0195-668X. 38, s. 3258–3271. doi: 10.1093/eurheartj/ehx643.
Kjeldsen, Sverre (2017). Hypertension and cardiovascular risk: General aspects. Pharmacological Research. ISSN 1043-6618. 129, s. 95–99. doi: 10.1016/j.phrs.2017.11.003.
Prestgaard, Erik Edvard; Hodnesdal, Christian; Engeseth, Kristian; Erikssen, Jan Emil; Bodegard, Johan & Liestøl, Knut [Vis alle 10 forfattere av denne artikkelen] (2017). Long-term predictors of stroke in healthy middle-aged men. International Journal of Stroke. ISSN 1747-4930. 13(3), s. 292–300. doi: 10.1177/1747493017730760.
Mahfoud, Felix; Schmieder, Roland E.; Azizi, Michel; Pathak, Atul; Sievert, Horst & Tsioufis, Costas [Vis alle 29 forfattere av denne artikkelen] (2017). Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: State of the art and considerations for the future. European Heart Journal. ISSN 0195-668X. 38(44), s. 3272–3281. doi: 10.1093/eurheartj/ehx215.
Jacobs, Lotte; Persu, Alexandre; Huang, Qi-Fang; Lengelé, Jean-Philippe; Thijs, Lutgarde & Hammer, Frank [Vis alle 21 forfattere av denne artikkelen] (2017). Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure. ISSN 0803-7051. 26(6), s. 321–331. doi: 10.1080/08037051.2017.1320939.
Okin, Peter M.; Hille, Darcy A.; Kjeldsen, Sverre Erik & Devereux, Richard B (2017). Combining ECG criteria for left ventricular hypertrophy improves risk prediction in patients with hypertension. Journal of the American Heart Association (JAHA). ISSN 2047-9980. 6(11). doi: 10.1161/JAHA.117.007564. Fulltekst i vitenarkiv
Persu, Alexandre; Gordin, Daniel; Jacobs, Lotte; Thijs, Lutgarde; Bots, Michiel L & Spiering, Wilko [Vis alle 27 forfattere av denne artikkelen] (2017). Blood pressure response to renal denervation is correlated with baseline blood pressure variability: a patient-levelmeta-analysis. Journal of Hypertension. ISSN 0263-6352. 36(2), s. 221–229. doi: 10.1097/HJH.0000000000001582.
Mariampillai, Julian Eek; Engeseth, Kristian; Kjeldsen, Sverre Erik; Grundvold, Irene; Liestøl, Knut & Erikssen, Gunnar [Vis alle 9 forfattere av denne artikkelen] (2017). Exercise systolic blood pressure at moderate workload predicts cardiovascular disease and mortality through 35 years of follow-up in healthy, middle-aged men. Blood Pressure. ISSN 0803-7051. 26(4), s. 229–236. doi: 10.1080/08037051.2017.1291276.
Fadl Elmula, Fadl Elmula M.; Feng, Ying-Mei; Jacobs, Lotte; Larstorp, Anne Cecilie Kjeldsen; Kjeldsen, Sverre Erik & Persu, Alexandre [Vis alle 7 forfattere av denne artikkelen] (2017). Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Pressure. ISSN 0803-7051. 26(4), s. 195–203. doi: 10.1080/08037051.2017.1311769.
Kjeldsen, Sverre Erik & Mancia, Giuseppe (2017). The un-observed automated office blood pressure measurement technique used in the SPRINT study points to a standard target office systolic blood pressure <140 mmHg. Current Hypertension Reports. ISSN 1522-6417. 19:3, s. 1–2. doi: 10.1007/s11906-017-0700-y.
Tanoue, Michael T; Kjeldsen, Sverre Erik; Devereux, Richard B & Okin, Peter M. (2017). Relationship between abnormal P-wave terminal force in lead V1 and left ventricular diastolic dysfunction in hypertensive patients: the LIFE study. Blood Pressure. ISSN 0803-7051. 26(2), s. 94–101. doi: 10.1080/08037051.2016.1215765.
Okin, Peter M.; Kjeldsen, Sverre & Devereux, Richard B. (2016). Impact of achieved systolic blood pressure on renal function in hypertensive patients. European Heart Journal - Quality of Care and Clinical Outcomes. ISSN 2058-5225. 2(4), s. 271–276. doi: 10.1093/ehjqcco/qcw017.
Palatini, Paolo; Rosei, Enrico Agabiti; Casiglia, Edoardo; Chalmers, John; Ferrari, Roberto & Grassi, Guido [Vis alle 16 forfattere av denne artikkelen] (2016). Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. Journal of Hypertension. ISSN 0263-6352. 34(5), s. 813–821. doi: 10.1097/HJH.0000000000000865.
Mancia, G.; Cha, Gloria; Gil-Extremera, Blas; Harvey, P; Lewin, Andrew J & Villa, Giuseppe [Vis alle 7 forfattere av denne artikkelen] (2016). Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial. Journal of Human Hypertension. ISSN 0950-9240. 31(3), s. 178–188. doi: 10.1038/jhh.2016.54.
Aksnes, Tonje Amb; Kjeldsen, Sverre Erik; Rostrup, Morten; Holzhauer, Björn; Hua, Tsushung A. & Julius, Stevo (2016). Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Blood Pressure. ISSN 0803-7051. 25(4), s. 235–240. doi: 10.3109/08037051.2015.1134071.
Mariampillai, Julian Eek; Eskås, Per Anders; Heimark, Sondre; Kjeldsen, Sverre Erik; Narkiewicz, Krzysztof & Mancia, Giuseppe (2016). A case for less intensive blood pressure control: it matters to achieve target blood pressure early and sustained below 140/90 mmHg. Progress in cardiovascular diseases. ISSN 0033-0620. 59(3), s. 209–218. doi: 10.1016/j.pcad.2016.09.002.
Kjeldsen, Sverre Erik; Dzongowski, P; Li, N; Wang, L & Radlmaier, A (2016). Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study. Journal of Clinical Pharmacy and Therapeutics. ISSN 0269-4727. 41(6), s. 695–702. doi: 10.1111/jcpt.12451.
Engeseth, Kristian; Hodnesdal, Christian; Grundvold, Irene; Liestøl, Knut; Gjesdal, Knut & Kjeldsen, Sverre Erik [Vis alle 9 forfattere av denne artikkelen] (2016). Temporal reduction in chronotropic index predicts risk of cardiovascular death among healthy middle-aged men: A 28-year follow-up study. Journal of the American Heart Association (JAHA). ISSN 2047-9980. 5:e004555, s. 1–12. doi: 10.1161/JAHA.116.004555. Vis sammendrag
Background Chronotropic index is a standardized measure of heart rate (HR) increment during exercise that reflects the combined effects of age, resting HR, and physical fitness. Low chronotropic index has been reported to predict disease and death. We tested whether temporal change in chronotropic index over 7 years influenced risk of cardiovascular death through up to 28 years. Methods and Results Chronotropic index was calculated ([achieved maximal HR−resting HR]/[age‐predicted maximal HR−resting HR]) after a symptom‐limited bicycle ECG exercise test in 1420 healthy men at 2 examinations 7 years apart, in 1972 and 1979. Events of cardiovascular death were registered by manual scrutiny of all participants’ hospital charts and the Norwegian Cause of Death Registry. The participants were divided into quartiles of temporal change in chronotropic index, with quartile one having the most negative value. Cox proportional hazard regression models were used to estimate risks and adjusted for classical cardiovascular risk factors. Incidence of cardiovascular death was 310 (22%) during median of 21 years of follow‐up. After multivariable adjustment, and comparison with quartile four (mean +0.11), quartiles one (−0.16), two (−0.04), and three (+0.02) were associated with hazard ratios 1.50 (95% CI 1.10–2.05), 1.10 (0.79–1.53), and 1.04 (0.74–1.45) for cardiovascular death. Results remained robust also after exclusion of 31 participants with exercise ECG‐induced signs of coronary ischemia. Conclusions Temporal reduction in chronotropic index was associated with increased long‐term risk of cardiovascular death and might be a clinically important predictor when assessing risk in healthy individuals over a longer time.
Kjeldsen, Sverre Erik; Stenehjem, Aud Eldrid; Os, Ingrid; Van de Borne, Philippe; Burnier, Michel & Narkiewicz, Krzysztof [Vis alle 9 forfattere av denne artikkelen] (2016). Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Pressure. ISSN 0803-7051. 25(6), s. 333–336. doi: 10.1080/08037051.2016.1236329.
Kjeldsen, Sverre Erik; Cha, Gloria; Villa, Giuseppe & Mancia, Giuseppe (2016). Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses. Journal of clinical pharmacology. ISSN 0091-2700. 56(9), s. 1120–1129. doi: 10.1002/jcph.712.
Okin, Peter M.; Kamel, Hooman; Kjeldsen, Sverre Erik & Devereux, Richard B. (2016). Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy. Journal of Hypertension. ISSN 0263-6352. 34(9), s. 1831–1837. doi: 10.1097/HJH.0000000000000989.
Berra, Elena; Azizi, Michel; Capron, Arnaud; Høieggen, Aud; Rabbia, Franco & Kjeldsen, Sverre Erik [Vis alle 9 forfattere av denne artikkelen] (2016). Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. ISSN 0194-911X. 68(2), s. 297–306. doi: 10.1161/HYPERTENSIONAHA.116.07464.
Persu, Alexandre; Kjeldsen, Sverre Erik; Staessen, Jan A. & Azizi, Michel (2016). Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges. Current Hypertension Reports. ISSN 1522-6417. 18(1), s. 1–11. doi: 10.1007/s11906-015-0610-9.
Kjeldsen, Sverre Erik; Lund-Johansen, Per; Nilsson, Peter M. & Mancia, Giuseppe (2016). Unattended blood pressure measurements in the systolic blood pressure intervention trial: Implications for entry and achieved blood pressure values compared with other trials. Hypertension. ISSN 0194-911X. 67(5), s. 808–812. doi: 10.1161/HYPERTENSIONAHA.116.07257.
Kjeldsen, Sverre Erik; Berge, Eivind; Bangalore, Sripal; Messerli, Franz H.; Mancia, Giuseppe & Holzhauer, Bjoern [Vis alle 11 forfattere av denne artikkelen] (2016). No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Pressure. ISSN 0803-7051. 25(2), s. 83–92. doi: 10.3109/08037051.2015.1106750.
Mancia, Giuseppe; Kjeldsen, Sverre Erik; Zappe, Dion H.; Holzhauer, Bjoern; Hua, Tsushung A. & Zanchetti, Alberto [Vis alle 8 forfattere av denne artikkelen] (2016). Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. European Heart Journal. ISSN 0195-668X. doi: 10.1093/eurheartj/ehv633.
Skårn, Sigrid Nordang; Eggesbø, Heidi Beate; Flaa, Arnljot; Kjeldsen, Sverre Erik; Rostrup, Morten & Brunborg, Cathrine [Vis alle 8 forfattere av denne artikkelen] (2016). Predictors of abdominal adipose tissue compartments: 18-year follow-up of young men with and without family history of diabetes. European journal of internal medicine. ISSN 0953-6205. 29, s. 26–31. doi: 10.1016/j.ejim.2015.11.027.
Engeseth, Kristian; Hodnesdal, Christian; Grundvold, Irene; Liestøl, Knut; Gjesdal, Knut & Erikssen, Gunnar [Vis alle 10 forfattere av denne artikkelen] (2016). Heart rate reserve predicts cardiovascular death among physically unfit but otherwise healthy middle-aged men: a 35-year follow-up study. European Journal of Preventive Cardiology (EJPC). ISSN 2047-4873. 23(1), s. 59–66. doi: 10.1177/2047487314553202.
Kjeldsen, Sverre; Fadl Elmula, Fadl Elmula M.; Os, Ingrid; Persu, Alexandre; Jin, Yu & Staessen, Jan A. (2015). Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 1(1), s. 48–56. doi: 10.1093/ehjcvp/pvu009.
Fadl Elmula, Fadl Elmula M.; Larstorp, Anne Cecilie Kjeldsen; Kjeldsen, Sverre Erik; Persu, Alexandre; Jin, Yu & Staessen, Jan A (2015). Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension. Frontiers in Physiology. ISSN 1664-042X. doi: 10.3389/fphys.2015.00009.
Fadl Elmula, Fadl Elmula M.; Rebora, Paola; Talvik, Anneli; Salerno, Sabrina; Miszkowska-Nagórna, Eliza & Liu, Xiaoqiu [Vis alle 17 forfattere av denne artikkelen] (2015). A randomized and controlled study of noninvasive hemodynamicmonitoring as a guide to drug treatment of uncontrolled hypertensive patients. Journal of Hypertension. ISSN 0263-6352. 33(12), s. 2534–2545. doi: 10.1097/HJH.0000000000000749.
Hasvold, Lars Pål; Thuresson, Marcus; Sundström, Johan; Hammar, Niklas; Kjeldsen, Sverre Erik & Johansson, Gunnar [Vis alle 8 forfattere av denne artikkelen] (2015). Association between paradoxical HDL cholesterol decrease and risk of major adverse cardiovascular events in patients initiated on statin treatment in a primary care setting. Clinical drug investigation. ISSN 1173-2563. 26(3), s. 225–233. doi: 10.1007/s40261-015-0372-9. Fulltekst i vitenarkiv Vis sammendrag
Background and Objectives Statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and lowdensity lipoprotein cholesterol (LDL-C) are unrelated. Many patients initiated on statins experience a paradoxical decrease in HDL-C. The aim of this study was to evaluate the association between a decrease in HDL-C and risk of major adverse cardiovascular events (MACE). Methods Data from 15,357 primary care patients initiated on statins during 2004–2009 were linked with data from mandatory national hospital, drug-dispensing, and causeof- death registers, and were grouped according to HDL-C change: decreased C0.1 mmol/L, unchanged ±0.1 or C0.1 mmol/L increased. To evaluate the association between decrease in HDL-C and risk of MACE, a sample of propensity score-matched patients from the decreased and unchanged groups was created, using the latter group as reference. MACE was defined as myocardial infarction, unstable angina pectoris, ischaemic stroke, or cardiovascular mortality. Cox proportional hazards models were used to estimate relative risks. Results HDL-C decreased in 20 %, was unchanged in 58%, and increased in 22 % of patients initiated on statin treatment (96 % treated with simvastatin). The propensity score-matched sample comprised 5950 patients with mean baseline HDL-C and LDL-C of 1.69 and 4.53 mmol/L, respectively. HDL-C decrease was associated with 56 % higher MACE risk (hazard ratio 1.56; 95 % confidence interval 1.12–2.16; p\0.01) compared with the unchanged HDL-C group. Conclusions Paradoxical statin-induced reduction in HDL-C was relatively common and was associated with increased risk of MACE.
Fadl Elmula, Fadl Elmula M.; Rebora, Paola; Talvik, Anneli; Salerno, Sabrina; Miszkowska-Nagorna, Eliza & Liu, Xiaoqiu [Vis alle 17 forfattere av denne artikkelen] (2015). A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients. Journal of Hypertension. ISSN 0263-6352. 33(12), s. 2534–2545. doi: 10.1097/HJH.0000000000000749.
Vishram, Julie K.K.; Dahlöf, Bjørn; Devereux, Richard B; Ibsen, Hans; Kjeldsen, Sverre Erik & Lindholm, Lars H. [Vis alle 11 forfattere av denne artikkelen] (2015). Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. Journal of Hypertension. ISSN 0263-6352. 33(12), s. 2422–2430. doi: 10.1097/HJH.0000000000000739.
Okin, Peter M.; Kjeldsen, Sverre Erik & Devereux, Richard B (2015). Systolic Blood Pressure Control and Mortality After Stroke in Hypertensive Patients. Stroke. ISSN 0039-2499. 46(8), s. 2113–2118. doi: 10.1161/STROKEAHA.115.009592.
Fadl Elmula, Fadl Elmula M.; Jin, Yu; Yang, Wen-Yi; Thijs, Lutgarde; Lu, Yi-Chao & Larstorp, Anne Cecilie Kjeldsen [Vis alle 20 forfattere av denne artikkelen] (2015). Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Pressure. ISSN 0803-7051. 24(5), s. 263–274. doi: 10.3109/08037051. Vis sammendrag
Objective The blood pressure (BP)-lowering effect of renal sympathetic nervous denervation (RDN) in resistant hyperten- sion (rHT) shows large variation among studies. Methods. We meta-analyzed summary statistics of randomized clinical trials on RDN in rHT. For continuous outcomes, we assessed heterogeneity by Cochran’s Q test and used random-effect models weighted for the inverse of the variance. We assessed safety by assessing the risk of major adverse events from stratified contingency tables. Results. Of 5652 patients screened in seven trials, 985 (17.4%) qualified and were randomized to control ( n 397) or RDN with SYMPLICITY catheters (n 588). Follow-up was 6 months. In both control and RDN patients, antihypertensive treatment was continued or optimized. At enrolment, age averaged 58.1 years, systolic/ diastolic office and 24 h BP 168.5/93.3 mmHg and 151.8/86.1 mmHg, respectively, and estimated glomerular filtrationrate (eGFR) 79.3 ml/min/1.73 m2 For BP outcomes, there was heterogeneity among trials. Pooled effects (control minus RDN) were 4.9/ 3.5 mmHg (95% confidence interval, 20.9 to 11.1/ 8.9 to 1.9) for office BP, 2.8/1.5 mmHg (6.5 to 0.8/3.3 to 0.4) for 24 h BP and 0.81 ml/min/1.73 m (1.69 to 3.30) for eGFR. Removing one trial at a time produced confirmatory results. Adverse events occurred in 7.4% and 9.9% of control and RDN patients, respectively (p 0.24). Conclusion. In selected rHT patients maintained on antihypertensive drugs, RDN with the SYMPLICITY systems does not significantly decrease BP but is safe. Future trials with next-generation catheters should aim at identifying responders in patients with evidence of sympathetic nervous overactivity.
Skårn, Sigrid Nordang; Flaa, Arnljot; Kjeldsen, Sverre Erik; Rostrup, Morten; Brunborg, Cathrine & Reims, Henrik Mikael [Vis alle 9 forfattere av denne artikkelen] (2015). Family history of hypertension and serumtriglycerides predict future insulin sensitivity: A17-year follow-up study of youngmen. Journal of Hypertension. ISSN 0263-6352. 33(9), s. 1845–1852. doi: 10.1097/HJH.0000000000000632.
Okin, Peter M.; Hille, Darcy A.; Wachtell, Kristian; Kjeldsen, Sverre Erik; Boman, Kurt & Dahlöf, Björn [Vis alle 7 forfattere av denne artikkelen] (2015). Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. Journal of Hypertension. ISSN 0263-6352. 33(7), s. 1480–1486. doi: 10.1097/HJH.0000000000000559.
Mahfoud, Felix; Böhm, Michael; Azizi, Michel; Pathak, Atul; Durand Zaleski, Isabelle & Ewen, Sebastian [Vis alle 30 forfattere av denne artikkelen] (2015). Proceedings from the European clinical consensus conference for renal denervation: Considerations on future clinical trial design. European Heart Journal. ISSN 0195-668X. 36(33), s. 2219–2227. doi: 10.1093/eurheartj/ehv192.
Okin, Peter M.; Hille, Darcy A.; Larstorp, Anne Cecilie Kjeldsen; Wachtell, Kristian; Kjeldsen, Sverre Erik & Dahlöf, Björn [Vis alle 7 forfattere av denne artikkelen] (2015). Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension. ISSN 0194-911X. 66(2), s. 368–373. doi: 10.1161/HYPERTENSIONAHA.115.05728.
Holme, Ingar Morten K & Kjeldsen, Sverre Erik (2015). Long-term survival in the randomized trial of drug treatment in mild to moderate hypertension of the Oslo study 1972-3. European journal of internal medicine. ISSN 0953-6205. 26(2), s. 123–126. doi: 10.1016/j.ejim.2015.01.013. Vis sammendrag
Background: In the Oslo cardiovascular study of 1972–3 a 5-year randomized trial in mild to moderate hypertension was performed. Several changes in treatment practices have been recommended since that time. We followed the mortality patterns up to 40 years. Methods: Invited to the Oslo study screening were 25,915 middle-aged men and 16,203 (63%) participated. Reexaminations were done to select suitable participants into the trial. Men had blood pressure 150–179/95– 109 mm Hg and the active group (n = 406) was treated with thiazides, alpha-methyldopa and propranolol versus untreated controls (n = 379). Cox regression analysis was used for statistical analyses. Results: There was no trend towards reduction in total mortality by treatment. A nominally significant increase in risk of death at first myocardial infarction was observed in the trial treatment group across the follow-up period, HR = 1.51 (1.01–2.25); (P = 0.042). The excess risk developed rapidly during the first 15 years, but the gap between the groups diminished to a large extent during the next 15 years, but the curves stayed at a certain distance for the last 10 years. Cerebrovascular death tended to be non-significantly reduced, HR = 0.85 (0.52–1.41). Conclusions: Drug treatment of mild hypertensive men initiated in the 1970s did not reduce mortality at first MI or total mortality. However, during the period (late 1980s and whole 1990s), when large changes in hypertension treatment practices occurred into regimes with more use of combination therapies including metabolically neutral drugs at lower doses, beneficial effects on MI mortality could be observed.
Skårn, Sigrid Nordang; Flaa, Arnljot; Kjeldsen, Sverre Erik; Rostrup, Morten; Brunborg, Cathrine & Reims, Henrik Mikael [Vis alle 9 forfattere av denne artikkelen] (2015). High screening blood pressure at young age predicts future masked hypertension: A 17 year follow-up study. Blood Pressure. ISSN 0803-7051. 24(3), s. 131–138. doi: 10.3109/21695717.2015.1030889.
Persu, Alexandre; Jin, Yu; Fadl El Mula, Fadl El Mula Mohamed; Renkin, Jean; Høieggen, Aud & Kjeldsen, Sverre Erik [Vis alle 7 forfattere av denne artikkelen] (2015). Renal denervation in treatment-resistant hypertension: A reappraisal. Current opinion in pharmacology (Print). ISSN 1471-4892. 21, s. 48–52. doi: 10.1016/j.coph.2014.12.013.
Skoglund, Per H; Svensson, Per; Asp, Joline; Dahløf, Bjørn; Kjeldsen, Sverre Erik & Jamerson, Kenneth [Vis alle 10 forfattere av denne artikkelen] (2015). Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial. The Journal of Clinical Hypertension. ISSN 1524-6175. 17(2), s. 141–146. doi: 10.1111/jch.12460.
Kjeldsen, Sverre Erik; Julius, Stevo; Dahlöf, Björn & Weber, Michael A. (2015). Physician (investigator) inertia in apparent treatment-resistant hypertension – Insights from large randomized clinical trials. Lennart Hansson Memorial Lecture . Blood Pressure. ISSN 0803-7051. 24(1), s. 1–6. doi: 10.3109/08037051.2014.946787.
Zanned, F.; Stough, Wendy Gattis; Mahfoud, Felix; Bakris, George L.; Kjeldsen, Sverre Erik & Kieval, Robert S. [Vis alle 12 forfattere av denne artikkelen] (2015). Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. Hypertension. ISSN 0194-911X. 65(1), s. 5–15. doi: 10.1161/HYPERTENSIONAHA.114.04057.
Persu, Alexandre; Azizi, Michel; Jin, Yu; Volz, Sebastian; Rosa, Jan & Fadl El Mula, Fadl El Mula Mohamed [Vis alle 15 forfattere av denne artikkelen] (2014). Hyperresponders vs. nonresponder patients after renal denervation: do they differ? Journal of Hypertension. ISSN 0263-6352. 32(12), s. 2422–2427. doi: 10.1097/HJH.0000000000000347.
Kjeldsen, Sverre Erik; Sica, Domenic A.; Haller, Hermann; Cha, Gloria; Gil-Extremera, Blas & Harvey, Peter [Vis alle 10 forfattere av denne artikkelen] (2014). Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. Journal of Hypertension. ISSN 0263-6352. 32(12), s. 2488–2498. doi: 10.1097/HJH.0000000000000331.
Mariampillai, Julian Eek; Fadl El Mula, Fadl El Mula Mohamed; HOFFMANN, PAVEL; Sørensen, Heidi; Høieggen, Aud & Kjeldsen, Sverre Erik (2014). En oppdatering på renal denervasjon som behandling av terapiresistent hypertensjon. Hjerteforum. ISSN 0802-1465. 27(4), s. 47–55.
Hasvold, Lars Pål; Bodegard, Johan; Thuresson, Marcus; Stålhammar, J.; Hammar, N. & Sundstrom, J [Vis alle 8 forfattere av denne artikkelen] (2014). Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients. Journal of Human Hypertension. ISSN 0950-9240. 28(11), s. 663–669. doi: 10.1038/jhh.2014.43. Fulltekst i vitenarkiv
Kjeldsen, Sverre Erik; Feldman, Ross D.; Lisheng, Liu; Mourad, Jean-Jacques; Chiang, Chern-En & Zhang, Weizhong [Vis alle 9 forfattere av denne artikkelen] (2014). Updated national and international hypertension guidelines: a review of current recommendations. Drugs. ISSN 0012-6667. 74(17), s. 2033–2051. doi: 10.1007/s40265-014-0306-5.
Sandset, Else Charlotte; Berge, Eivind; Kjeldsen, Sverre Erik; Julius, Stevo; Holzhauer, B & Krarup, Lars-Henrik [Vis alle 7 forfattere av denne artikkelen] (2014). Heart rate as a predictor of stroke in high-risk, hypertensive patients with previous stroke or transient ischemic attack. Journal of Stroke & Cerebrovascular Diseases. ISSN 1052-3057. 23(10), s. 2814–2818. doi: 10.1016/j.jstrokecerebrovasdis.2014.07.009.
Kjeldsen, Sverre Erik; Aksnes, Tonje Amb & Ruilope, Luis M. (2014). Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. Drugs in R&D. ISSN 1174-5886. 14(2), s. 31–43. doi: 10.1007/s40268-014-0049-5.
Kjeldsen, Sverre Erik; Fadl El Mula, Fadl El Mula Mohamed; Persu, Alexandre; Jin, Yu & Staessen, Jan A. (2014). Renal sympathetic denervation in the aftermath of Symplicity HTN-3. Blood Pressure. ISSN 0803-7051. 23(5), s. 256–261. doi: 10.3109/08037051.2014.953861.
Persu, A.; Jin, Y.; Azizi, M.; Baelen, M.; Völz, S. & Elvan, A. [Vis alle 25 forfattere av denne artikkelen] (2014). Blood pressure changes after renal denervation at 10 European expert centers. Journal of Human Hypertension. ISSN 0950-9240. 28(3), s. 150–156. doi: 10.1038/jhh.2013.88.
Neldam, Steen; Schumacher, Helmut; Kjeldsen, Sverre Erik & Neutel, Joel M. (2014). Telmisartan in combination with hydrochlorothiazide 12.5mg for the management of patients with hypertension. Current Medical Research and Opinion. ISSN 0300-7995. 30(9), s. 1715–1724. doi: 10.1185/03007995.2014.924912.
Persu, Alexandre; Jin, Yu; Baelen, Marie; Vink, Eva; Verloop, Willemien L. & Schmidt, Bernhard [Vis alle 29 forfattere av denne artikkelen] (2014). Eligibility for renal denervation: Experience at 11 European expert centers. Hypertension. ISSN 0194-911X. 63(6), s. 1319–1325. doi: 10.1161/HYPERTENSIONAHA.114.03194.
Fadl El Mula, Fadl El Mula Mohamed; HOFFMANN, PAVEL; Larstorp, Anne Cecilie Kjeldsen; Fossum, Eigil; Brekke, Magne & Kjeldsen, Sverre Erik [Vis alle 13 forfattere av denne artikkelen] (2014). Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. ISSN 0194-911X. 63(5), s. 991–999. doi: 10.1161/HYPERTENSIONAHA.114.03246.
Okin, Peter M.; Bang, Casper N.; Wachtell, Kristian; Hille, Darcy A.; Kjeldsen, Sverre Erik & Julius, Stevo [Vis alle 8 forfattere av denne artikkelen] (2014). Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. American Journal of Hypertension. ISSN 0895-7061. 27(7), s. 966–972. doi: 10.1093/ajh/hpu006.
Persu, Alexandre; Jin, Yu; Fadl El Mula, Fadl El Mula Mohamed; Jacobs, Lotte; Renkin, Jean & Kjeldsen, Sverre Erik (2014). Renal denervation after symplicity HTN-3: An update. Current Hypertension Reports. ISSN 1522-6417. 16(8). doi: 10.1007/s11906-014-0460-x.
Okin, Peter M.; Hille, Darcy A.; Kjeldsen, Sverre Erik; Dahlöf, Björn & Devereux, Richard B. (2014). Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment. Blood Pressure. ISSN 0803-7051. 23(2), s. 71–80. doi: 10.3109/08037051.2013.791414.
Sørensen, Heidi; Fadl El Mula, Fadl El Mula Mohamed; Kjeldsen, Sverre Erik; Brekke, Magne; Gjønnæss, Eyvind & Hjørnholm, Ulla [Vis alle 13 forfattere av denne artikkelen] (2014). Renal sympatisk denervering ved terapiresistent hypertensjon. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 134(1), s. 32–36. doi: 10.4045/tidsskr.13.0276.
Kjeldsen, Sverre Erik; Mancia, Giuseppe; Schmieder, Roland; Mattheus, Michaela & Unger, Thomas (2013). An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. Expert Review of Cardiovascular Therapy. ISSN 1477-9072. 11(6), s. 673–682. doi: 10.1586/ERC.13.63.

Se alle arbeider i Cristin

Kreutz, Reinhold; Brunström, Mattias; Burnier, Michel; Grassi, Guido; Januszewicz, Andrzej & Kjeldsen, Sverre [Vis alle 10 forfattere av denne artikkelen] (2024). Beta-blocker bashing and downgrading in hypertension management: a fashionable trend representing a matter of concern. Journal of Hypertension. ISSN 0263-6352. 42(6), s. 966–967. doi: 10.1097/HJH.0000000000003735.
Kjeldsen, Sverre & Grassi, Guido (2024). The role of β-blockers in medical treatment. Current Medical Research and Opinion. ISSN 0300-7995. 40(1), s. 1–2. doi: 10.1080/03007995.2024.2324138.
Kjeldsen, Sverre; Egan, Brent M.; Burnier, Michel; Narkiewicz, Krzysztof; Kreutz, Reinhold & Mancia, Giuseppe (2024). Highlights of the 2023 European Society of Hypertension Guidelines: what has changed in the management of hypertension in patients with cardiac diseases? Blood Pressure. ISSN 0803-7051. 33(1). doi: 10.1080/08037051.2024.2329571.
Mancia, Giuseppe & Kjeldsen, Sverre (2023). Randomized Clinical Outcome Trials in Hypertension. Hypertension. ISSN 0194-911X. 81(1), s. 17–23. doi: 10.1161/HYPERTENSIONAHA.123.21725.
Kjeldsen, Sverre; Mariampillai, Julian Eek & Høieggen, Aud (2023). Uric acid and left ventricular mass in prediction of cardiovascular risk-New insight from the URRAH study . European journal of internal medicine. ISSN 0953-6205. 114, s. 45–46. doi: 10.1016/j.ejim.2023.05.016.
Mariampillai, Julian Eek & Kjeldsen, Sverre (2023). Real-world data show the effect of statins in primary prevention. European Journal of Preventive Cardiology (EJPC). ISSN 2047-4873. 30(17), s. 1881–1882. doi: 10.1093/eurjpc/zwad231.
Mariampillai, Julian Eek; Halvorsen, Lene Vernås; Larstorp, Anne Cecilie Kjeldsen; Heimark, Sondre; Waldum-Grevbo, Bård & Kjeldsen, Sverre [Vis alle 10 forfattere av denne artikkelen] (2023). Diabetes og kronisk nyresykdom. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(12). doi: 10.4045/tidsskr.22.0822.
Kjeldsen, Sverre; Burnier, Michel; Narkiewicz, Krzysztof; Kreutz, Reinhold & Mancia, Giuseppe (2023). Key questions regarding the SYMPLICITY HTN-3 trial. The Lancet. ISSN 0140-6736. 401(10385), s. 1336–1337. doi: 10.1016/S0140-6736(23)00340-9.
Burnier, Michel; Brguljan, Jana; Algharably, Engi Abd Elhady; Kjeldsen, Sverre; Narkiewicz, Krzysztof & Egan, Brent [Vis alle 8 forfattere av denne artikkelen] (2023). Women’s health, cardiovascular risk and hypertension: the perspective still needs to improve. Blood Pressure. ISSN 0803-7051. 32(1). doi: 10.1080/08037051.2023.2193648.
Kjeldsen, Sverre; Egan, Brent M.; Narkiewicz, Krzysztof; Kreutz, Reinhold; Burnier, Michel & Oparil, Suzanne [Vis alle 7 forfattere av denne artikkelen] (2023). TIME to face the reality about evening dosing of antihypertensive drugs in hypertension. Blood Pressure. ISSN 0803-7051. 32(1), s. 1–3. doi: 10.1080/08037051.2022.2142512.
Kjeldsen, Sverre; Brunström, Mattias; Thomopoulos, Costas; Carlberg, Bo; Kreutz, Reinhold & Mancia, Giuseppe (2022). Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes. The Lancet Diabetes and Endocrinology. ISSN 2213-8587. 10(12). doi: 10.1016/S2213-8587(22)00312-6.
Narkiewicz, Krzysztof; Kjeldsen, Sverre; Egan, Brent M.; Kreutz, Reinhold & Burnier, Michel (2022). Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure. Blood Pressure. ISSN 0803-7051. 31(1), s. 207–209. doi: 10.1080/08037051.2022.2107483.
Egan, Brent M.; Kjeldsen, Sverre; Narkiewicz, Krzysztof; Kreutz, Reinhold & Burnier, Michel (2022). Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions. Blood Pressure. ISSN 0803-7051. 31(1), s. 164–168. doi: 10.1080/08037051.2022.2095254.
Halvorsen, Lene Vernås; Gognstad, Stine; Søraas, Camilla Lund; Ågnes, Camilla; Hjørnholm, Ulla & Kjær, Vibeke Norheim [Vis alle 21 forfattere av denne artikkelen] (2022). Implications of CYP2D6 polymorphisms for therapeutic drug monitoring in patients with hypertension. Journal of Hypertension. ISSN 0263-6352. 40. doi: 10.1097/01.hjh.0000838764.61491.a8.
Mariampillai, Julian Eek; Kjeldsen, Sverre; Gjesdal, Knut Tjøl & Skretteberg, Torger (2022). Blood pressure during moderate or maximal exercise: hardly two sides of the same coin. Journal of Hypertension. ISSN 0263-6352. 40(6), s. 1243–1244. doi: 10.1097/HJH.0000000000003121.
Kjeldsen, Sverre; Zachs, Eran S.; Stokke, Ildri Maria; Wachtell, Kristian; Hille, Darcy A. & Høieggen, Aud [Vis alle 10 forfattere av denne artikkelen] (2022). Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypersensitive patients. Journal of Hypertension. ISSN 0263-6352. 40, s. e3–e3. doi: 10.1097/01.hjh.0000835312.59915.7b.
Kjeldsen, Sverre; Egan, Brent M.; Narkiewicz, Krzysztof; Kreutz, Reinhold; Burnier, Michel & Oparil, Suzanne (2022). Thirty years with LIFE—a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood Pressure. ISSN 0803-7051. 31(1), s. 125–128. doi: 10.1080/08037051.2022.2083578.
Burnier, Michel; Kjeldsen, Sverre; Narkiewicz, Krzysztof; Egan, Brent & Kreutz, Reinhold (2022). Hypertension management during the COVID-19 pandemic: what can we learn for the future? Blood Pressure. ISSN 0803-7051. 31(1), s. 47–49. doi: 10.1080/08037051.2022.2058909.
Burnier, Michel & Kjeldsen, Sverre (2022). A 30th anniversary and a glimpse of the future. Blood Pressure. ISSN 0803-7051. 31(1), s. 1–3. doi: 10.1080/08037051.2021.2021638.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2021). Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes–from single pill combinations to monitoring of a nationwide health insurance database. Blood Pressure. ISSN 0803-7051. 30(3), s. 143–144. doi: 10.1080/08037051.2021.1917192.
Burnier, Michel; Kjeldsen, Sverre; Narkiewicz, Krzysztof & Oparil, Suzanne (2021). Cuff-less measurements of blood pressure: are we ready for a change? Blood Pressure. ISSN 0803-7051. 30(4), s. 205–207. doi: 10.1080/08037051.2021.1956178.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2021). Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. Blood Pressure. ISSN 0803-7051. 30(1), s. 1–3. doi: 10.1080/08037051.2021.1862483.
Gjesdal, Knut & Kjeldsen, Sverre (2021). Fusk og feil i forskning og forskningsformidling. Indremedisineren. ISSN 1891-1617. s. 54–57.
Kjeldsen, Sverre E.; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2021). The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug. Blood Pressure. ISSN 0803-7051. doi: 10.1080/08037051.2021.1995975.
Kreutz, Reinhold; Kjeldsen, Sverre E. & Mancia, Giuseppe (2021). Why we do not need a single independent international hypertension clinical practice guideline. Journal of Hypertension. ISSN 0263-6352. 39(11), s. 2125–2127. doi: 10.1097/HJH.0000000000002940.
Narkiewicz, Krzysztof; Burnier, Michel; Kjeldsen, Sverre & Oparil, Suzanne (2021). Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection. Blood Pressure. ISSN 0803-7051. 30(5), s. 267–268. doi: 10.1080/08037051.2021.1975878.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2020). Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines? Blood Pressure. ISSN 0803-7051. 29(6), s. 341–343. doi: 10.1080/08037051.2020.1838766.
Kreutz, Reinhold; Kjeldsen, Sverre; Burnier, Michel; Narkiewicz, Krzysztof; Oparil, Suzanne & Mancia, Giuseppe (2020). Disregard the reported data from the HYGIA project: blood pressure medication not to be routinely dosed at bedtime. Journal of Hypertension. ISSN 0263-6352. 38(11), s. 2144–2145. doi: 10.1097/HJH.0000000000002671.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2020). The International Society of Hypertension Guidelines 2020–a new drug treatment recommendation in the wrong direction? Blood Pressure. ISSN 0803-7051. 29(5), s. 264–266. doi: 10.1080/08037051.2020.1806494.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2020). Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial? Blood Pressure. ISSN 0803-7051. 29(4), s. 199–201. doi: 10.1080/08037051.2020.1782595.
Kreutz, Reinhold; Kjeldsen, Sverre; Burnier, Michel; Narkiewicz, Krzysztof; Oparil, Suzanne & Mancia, Giuseppe (2020). Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. Blood Pressure. ISSN 0803-7051. 29(3), s. 135–136. doi: 10.1080/08037051.2020.1747696.
Kjeldsen, Sverre & Os, Ingrid (2020). Poor reproducibility of masked and white coat uncontrolled hypertension: Important new information on MUCH and WUCH. European Heart Journal. ISSN 0195-668X. 41(16), s. 1572–1574. doi: 10.1093/eurheartj/ehz703.
Burnier, Michel; Kjeldsen, Sverre; Narkiewicz, Krzysztof & Oparil, Suzanne (2020). How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers. Blood Pressure. ISSN 0803-7051. 29(2), s. 68–69. doi: 10.1080/08037051.2020.1726101.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2020). The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension. Blood Pressure. ISSN 0803-7051. 29(1), s. 1–2. doi: 10.1080/08037051.2020.1707440.
Kjeldsen, Sverre (2019). Hypertension and associated cardiovascular risk factors in Romania. Revista română de cardiologie. ISSN 1220-658X. 29(4), s. 556–557.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2019). Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes. Blood Pressure. ISSN 0803-7051. 28(6), s. 356–357. doi: 10.1080/08037051.2019.1678261.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2019). The PARAGON-Heart failure trial–another disappointment for heart failure patients with hypertension and preserved ejection fraction. Blood Pressure. ISSN 0803-7051. 28(5), s. 276–278. doi: 10.1080/08037051.2019.1664717.
Kjeldsen, Sverre & Os, Ingrid (2019). Are people with masked hypertension adherent to their antihypertensive medication? Hypertension. ISSN 0194-911X. 74(3), s. 497–498. doi: 10.1161/HYPERTENSIONAHA.119.13350.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2019). The PARAGON Heart Failure trial–ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. Blood Pressure. ISSN 0803-7051. 28(4), s. 215–216. doi: 10.1080/08037051.2019.1625523.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2019). Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited. Blood Pressure. ISSN 0803-7051. 28(3), s. 144–145. doi: 10.1080/08037051.2019.1614278.
Kjeldsen, Sverre; Atar, Dan & von Lueder, Thomas Gero (2019). Angiotensin receptor neprilysin inhibition for the treatment of hypertension: The neglected child in cardiovascular pharmacotherapy. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 5(2), s. 122–123. doi: 10.1093/ehjcvp/pvz005.
Kjeldsen, Sverre; Fadl Elmula, Fadl Elmula M. & Persu, Alexandre (2019). Future of Renal Sympathetic Denervation in the Treatment of Hypertension. Journal of the American College of Cardiology. ISSN 0735-1097. 73(13), s. 1643–1645. doi: 10.1016/j.jacc.2019.02.008.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2019). Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension? Blood Pressure. ISSN 0803-7051. 28(2), s. 75–76. doi: 10.1080/08037051.2019.1584975.
Burnier, Michel; Narkiewicz, Krzysztof; Kjeldsen, Sverre & Oparil, Suzanne (2019). New data on antihypertensive drugs and risk of cancer: should we worry? Blood Pressure. ISSN 0803-7051. 28(1), s. 1–3. doi: 10.1080/08037051.2019.1568182.
Kjeldsen, Sverre & Mancia, Giuseppe (2019). Unattended automated office vs. ambulatory blood pressure in people with high cardiovascular risk: implications for understanding the SPRINT results. Journal of Hypertension. ISSN 0263-6352. 37(1), s. 6–8. doi: 10.1097/HJH.0000000000001874.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2018). 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension. Blood Pressure. ISSN 0803-7051. 27(6). doi: 10.1080/08037051.2018.1530564.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2018). Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study. Blood Pressure. ISSN 0803-7051. 27(5), s. 247–248. doi: 10.1080/08037051.2018.1507621.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2018). Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure. Blood Pressure. ISSN 0803-7051. 27(4), s. 185–187. doi: 10.1080/08037051.2018.1486178.
Kjeldsen, Sverre; Mariampillai, Julian Eek & Nilsson, Peter M. (2018). Optimal blood pressure target in diabetic and nondiabetic hypertensive patients. Circulation Research. ISSN 0009-7330. 123(5), s. 528–530. doi: 10.1161/CIRCRESAHA.118.312763.
Mehlum, Maria Hollund; Liestøl, Knut; Kjeldsen, Sverre & Berge, Eivind (2018). Response to letters from Torp-Pedersen and colleagues and de Courson and colleagues. European Heart Journal. ISSN 0195-668X. 39(47), s. 4221–4221. doi: 10.1093/eurheartj/ehy605.
Kjeldsen, Sverre; Os, Ingrid & Nilsson, Peter M. (2018). Does intensive glucose control cancel out benefits of systolic blood pressure target <120 mmHg in patients with diabetes mellitus participating in accoRD? Hypertension. ISSN 0194-911X. 72(2), s. 291–293. doi: 10.1161/HYPERTENSIONAHA.118.11455.
Burnier, M.; Oparil, Suzanne; Narkiewicz, Krzysztof & Kjeldsen, Sverre (2018). New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden? Blood Pressure. ISSN 0803-7051. 27(2), s. 62–65. doi: 10.1080/08037051.2018.1430504.
Kjeldsen, Sverre & Esler, Murray D. (2018). Take a blood pressure pill or undergo renal denervation? The Lancet. ISSN 0140-6736. doi: 10.1016/S0140-6736(18)31126-7.
Narkiewicz, Krzysztof; Kjeldsen, Sverre; Burnier, Michel & Oparil, Suzanne (2018). Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions. Blood Pressure. ISSN 0803-7051. 27(1), s. 1–2. doi: 10.1080/08037051.2017.1407218.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2017). Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials. Blood Pressure. ISSN 0803-7051. 26(5), s. 257–258. doi: 10.1080/08037051.2017.1357110.
Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2017). The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke. Blood Pressure. ISSN 0803-7051. 26(3), s. 131–132. doi: 10.1080/08037051.2017.1292456.
Burnier, Michel; Narkiewicz, Krzysztof; Kjeldsen, Sverre & Oparil, Suzanne (2017). Renal denervation in hypertension: is it the end or the beginning of a SPYRAL? Blood Pressure. ISSN 0803-7051. 26(6), s. 319–320. doi: 10.1080/08037051.2017.1386539.
Messerli, Franz H.; Hofstetter, Louis; Agabiti-Rosei, Enrico; Burnier, Michel; Elliott, William J. & Franklin, Stanley S. [Vis alle 31 forfattere av denne artikkelen] (2017). Reply. Journal of Hypertension. ISSN 0263-6352. 35(11), s. 2327–2328. doi: 10.1097/HJH.0000000000001526.
Klemsdal, Tor Ole; Gjelsvik, Bjørn E.; Elling, Inger; Johansen, Sirin; Kjeldsen, Sverre Erik & Kristensen, Øivind [Vis alle 11 forfattere av denne artikkelen] (2017). Nye retningslinjer for forebygging av hjerte- og karsykdom. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 137(16), s. 1164–1168. doi: 10.4045/tidsskr.17.0109.
Messerli, Franz H.; Hofstetter, Louis; Agabiti-Rosei, Enrico; Burnier, Michel; Elliott, William J. & Franklin, Stanley S. [Vis alle 31 forfattere av denne artikkelen] (2017). Expertise: No longer a sine qua non for guideline authors? Journal of Hypertension. ISSN 0263-6352. 35(8), s. 1564–1566. doi: 10.1097/HJH.0000000000001435.
Messerli, Franz H.; Hofstetter, Louis; Agabiti-Rosei, Enrico; Burnier, Michel; Elliott, William J. & Franklin, Stanley S. [Vis alle 30 forfattere av denne artikkelen] (2017). Expertise: no longer a sine qua non for guideline authors? Hypertension. ISSN 0194-911X. 70(2), s. 235–237. doi: 10.1161/HYPERTENSIONAHA.117.09470.
Burnier, Michel; Narkiewicz, Krzysztof & Kjeldsen, Sverre Erik (2017). Prevention of heart failure mortality and hospitalizations in SPRINT, EMPA-REG, ALLHAT and HYVET: are diuretics the clue? Blood Pressure. ISSN 0803-7051. 26(4), s. 193–194. doi: 10.1080/08037051.2017.1332478.
Kjeldsen, Sverre Erik; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2017). The INTERSALT Study and the complex relationship between salt intake and blood pressure. Blood Pressure. ISSN 0803-7051. 26(2), s. 65–66. doi: 10.1080/08037051.2016.1274957.
Kjeldsen, Sverre Erik; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2017). The Global Burden of Disease Study 2015 and Blood Pressure. Blood Pressure. ISSN 0803-7051. 26(1). doi: 10.1080/08037051.2016.1267557.
Messerli, Franz H.; Bangalore, Sripal & Kjeldsen, Sverre Erik (2017). Letter by Messerli et al Regarding Article, "the Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure". Circulation. ISSN 0009-7322. 135(7), s. e45–e46. doi: 10.1161/CIRCULATIONAHA.116.025301.
Kjeldsen, Sverre Erik; Narkiewicz, Krzysztof & Oparil, Suzanne (2017). Blood Pressure in 2016: increased impact factor and change of editors. Blood Pressure. ISSN 0803-7051. 25(6), s. 331–332. doi: 10.1080/08037051.2016.1274957.
Kjeldsen, Sverre & Mancia, Giuseppe (2016). Unobserved automated office blood pressure measurement in the Systolic Blood Pressure Intervention Trial (SPRINT): systolic blood pressure treatment target remains below 140 mmHg. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 2(2), s. 79–80. doi: 10.1093/ehjcvp/pvw002.
Kjeldsen, Sverre Erik; Hedner, Thomas & Narkiewicz, Krzysztof (2016). HOPE-3, SPRINT, VALUE and a meta-analysis of trials in patients with diabetes support treatment of hypertension to a target below 140 mmHg. Blood Pressure. ISSN 0803-7051. 25(3), s. 131–132. doi: 10.1080/08037051.2016.1182857.
Kjeldsen, Sverre Erik & Lund-Johansen, Per (2016). Tynt grunnlag for å endre mål for blodtrykksbehandling. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 136(3), s. 209–210. doi: 10.4045/tidsskr.15.1298.
Hedner, Thomas; Kjeldsen, Sverre Erik; Narkiewicz, Krzysztof & Oparil, Suzanne (2016). The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease. Blood Pressure. ISSN 0803-7051. 25(5), s. 276–279. doi: 10.3109/08037051.2016.1139324.
Kjeldsen, Sverre Erik; Oparil, Suzanne; Narkiewicz, Krzysztof & Hedner, Thomas (2016). The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. Blood Pressure. ISSN 0803-7051. 25(1), s. 1–3. doi: 10.3109/08037051.2016.1096564.
Kjeldsen, Sverre Erik; Narkiewicz, Krzysztof; Hedner, Thomas & Mancia, Giuseppe (2016). The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg. Blood Pressure. ISSN 0803-7051. 25(2), s. 63–66. doi: 10.3109/08037051.2015.1130775.
Kjeldsen, Sverre Erik; Fadl Elmula, Fadl Elmula M. & Persu, Alexandre (2015). The setback of renal denervation should not backfire on sympathetic overactivity in hypertension. Journal of the American College of Cardiology. ISSN 0735-1097. 65(13), s. 1322–1323. doi: 10.1016/j.jacc.2015.01.037.
Kjeldsen, Sverre Erik; Sørensen, Heidi; Fadl El Mula, Fadl El Mula Mohamed; Brekke, Magne; Gjønnæss, Eyvind & Hjørnholm, Ulla [Vis alle 13 forfattere av denne artikkelen] (2014). Re: Renal sympatisk denervering ved terapiresistent hypertensjon. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 134(15), s. 1449–1450.
Kjeldsen, Sverre Erik; Narkiewicz, Krzysztof; Oparil, Suzanne & Hedner, Thomas (2014). Hypertension Management by Practice Guidelines. Blood Pressure. ISSN 0803-7051. 23(1), s. 1–2. doi: 10.3109/08037051.2014.881646.
Kjeldsen, Sverre Erik; Narkiewicz, Krzysztof; Oparil, Suzanne & Hedner, Thomas (2014). Renal denervation in treatment-resistant hypertension-Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials. Blood Pressure. ISSN 0803-7051. 23(3), s. 135–137. doi: 10.3109/08037051.2014.916896.
Mariampillai, Julian Eek; Fadl El Mula, Fadl El Mula Mohamed; HOFFMANN, PAVEL; Sørensen, Heidi; Høieggen, Aud & Kjeldsen, Sverre Erik (2014). Tvilsom effekt av renal denervering. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 134(17), s. 1643–1644. doi: 10.4045/tidsskr.13.0276..
Grundvold, Irene; Skretteberg, Torger; Liestøl, Knut; Erikssen, Gunnar; Engeseth, Kristian & Gjesdal, Knut [Vis alle 10 forfattere av denne artikkelen] (2013). Predictors of atrial fibrillation differ in men with high vs low physical fitness. European Heart Journal. ISSN 0195-668X. 34, s. 1041–1041.
Sandset, Else Charlotte; Kjeldsen, Sverre Erik; Rothwell, P.M.; Bath, P & Berge, E. (2013). Effects of candesartan on blood pressure variability in acute stroke: Is it important for prognosis? Results from the Scandinavian Candesartan Acute Stroke Trial. Cerebrovascular Diseases. ISSN 1015-9770. 35, s. 91–91.

Se alle arbeider i Cristin

Publisert 13. apr. 2011 11:40 - Sist endret 2. okt. 2020 12:01

Forskergrupper

Indremedisinsk forskergruppe